Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Laurie Monnier1, Stéphane Culine2, Luc Cormier3

  • 1GHU Paris Est, hôpital Tenon, service d'oncologie radiothérapie, 75020 Paris, France.

Presse Medicale (Paris, France : 1983)
|May 28, 2017
PubMed
Summary

High-risk prostate cancer management requires tailored treatment. Optimizing patient selection for combined therapies like hormonoradiotherapy improves outcomes for advanced prostate cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

UNICURE-HD: A Multicentric Retrospective Cohort Study of Single-Insertion Image-Guided high-Dose-Rate Brachytherapy for Locally Advanced Cervical Cancer in the Context of Limited Brachytherapy Access in France.

International journal of radiation oncology, biology, physics·2026
Same author

Perspectives of positron emission tomography with 2-deoxy-2-fluorine-18-flu-d-glucose (18fdg-pet) in predicting the histological response of high grade epithelial ovarian cancer to neoadjuvant chemotherapy. A primary descriptive study.

American journal of nuclear medicine and molecular imaging·2026
Same author

Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Does perioperative chemotherapy affect renal function after radical nephroureterectomy for upper tract urothelial carcinoma?

World journal of urology·2026

Area of Science:

  • Oncology
  • Urology
  • Radiation Oncology

Background:

  • High-risk prostate cancer is heterogeneous, necessitating refined patient selection criteria.
  • Current treatment strategies include hormonoradiotherapy, surgery, and systemic therapies.

Purpose of the Study:

  • To define improved criteria for selecting patients with high-risk prostate cancer for combined local or systemic treatments.
  • To explore the optimal modalities of radiotherapy and hormone therapy based on prognostic factors.

Main Methods:

  • Review of treatment modalities including hormonoradiotherapy, surgery, and chemotherapy.
  • Emphasis on pathological evaluation for accurate staging and avoiding overtreatment.
  • Consideration of treatment approaches for oligometastatic and metastatic prostate cancer.

Related Experiment Videos

Main Results:

  • Hormonoradiotherapy is a key treatment for high-risk prostate cancer.
  • Surgery can be combined with other treatments, with careful patient selection and technique adaptation.
  • Pathological evaluation is crucial to prevent overstaging and unnecessary androgen deprivation therapy.
  • Chemotherapy combined with hormone therapy is the standard for metastatic prostate cancer.

Conclusions:

  • Refined patient selection is vital for optimizing treatment in high-risk prostate cancer.
  • Treatment decisions for high-risk prostate cancer should be individualized based on prognostic factors.
  • Multimodal approaches, including surgery, radiotherapy, hormone therapy, and chemotherapy, play distinct roles depending on disease extent.